Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972981 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
A Phase 1 study, sponsored by ADC Therapeutics S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04972981 is a Phase 1 study that has completed, run by ADC Therapeutics S.A.. The registered enrollment target is 30 participants.
The verdict
NCT04972981, a Phase 1 study, has completed, sponsored by ADC Therapeutics S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objectives of this study are to identify the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
Interventions
- DRUG ADCT-901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04972981
The ClinicalTrials.gov registry entry for NCT04972981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADCT-901 is the first listed.
NCT04972981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04972981 about?
NCT04972981 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors". The primary objectives of this study are to identify the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
What is the current status of trial NCT04972981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-09-09. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT04972981?
The interventions under investigation include: ADCT-901 (DRUG).
Who is sponsoring clinical trial NCT04972981?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.